To investigate whether periprostatic fat, measured on a CT, is a better marker for prostate cancer aggressiveness in patients who underwent brachytherapy compared to BMI, focusing on the implications for treatment decisions.
Key Findings:
The median age was 66 years, with a median BMI of 25.8 kg/m2 and fat-density of 31.8%.
Patients with higher fat-density were significantly older, suggesting a potential link between age and fat distribution.
A significant association was found between fat-density groups and BMI, CFT, and periprostatic fat, indicating the need for further exploration of these relationships.
Interpretation:
Periprostatic fat may serve as a more reliable marker for prostate cancer aggressiveness than BMI alone, indicating the importance of visceral fat in cancer risk assessment and suggesting potential changes in clinical practice.
Limitations:
Short follow-up period limited the assessment of long-term outcomes, which may affect the validity of the findings.
The study was conducted in a single center, which may affect generalizability and the applicability of results to broader populations.
Conclusion:
Periprostatic fat density measured via CT could be a valuable indicator of prostate cancer aggressiveness, warranting further investigation in larger cohorts to validate these findings and explore their clinical implications.
